Navigation Links
Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the United States
Date:9/1/2009

SOUTH SAN FRANCISCO, Calif., Sept. 1 /PRNewswire/ -- Actelion Pharmaceuticals US, Inc., today announced the first commercial sales of a new 20 microgram per milliliter (mcg/mL) formulation of Ventavis(R), for the treatment of New York Heart Association Class III and IV pulmonary arterial hypertension (PAH). This increased strength formulation delivers the same dose of Ventavis in half the volume, which is expected to reduce inhalation time and further support patient compliance. The 20 mcg/mL formulation of Ventavis(R) is available immediately for pre-order, and fulfillment of initial prescriptions by specialty pharmacies is anticipated beginning the week of September 14.

"Ventavis(R) is the leading inhaled prostacylin therapy for patients with PAH, and this stronger formulation is a major advancement. Together with the easy-to-use, compact inhalation device called the I-neb AAD System, it will offer even more convenience to patients using Ventavis," said Kirk Taylor, M.D., Senior Vice President, U.S. Medical Group at Actelion Pharmaceuticals US.

"Ventavis(R) is the inhaled prostacyclin with the most extensive clinical experience, and is an extremely important treatment option for many patients with PAH. Shortening treatment times by 50% with the new 20 mcg/mL concentration will significantly benefit my patients," said Dr. Richard Channick, Professor of Medicine, Pulmonary and Critical Care Division, UC San Diego Medical Center and Editor-in-Chief, Advances in Pulmonary Hypertension.

About Ventavis(R)

Ventavis(R) is indicated for the treatment of pulmonary arterial hypertension (WHO Group 1) in patients with NYHA Class III or IV symptoms. In August 2009, the U.S. Food and Drug Adminsitration approved the new 20 mcg/ml formulation of Ventavis(R).

Ventavis(R) is an inhaled synthetic analog of prostacyclin (PGI2) that produces potent pulmona
'/>"/>

SOURCE Actelion Pharmaceuticals US, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007
2. Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information
3. GeneraMedix, Inc. Announces Sale of Innovative Epoprostenol Formulation to Actelion Ltd.
4. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
5. Novozymes Launches Enzyme to Reduce Acrylamide in Food
6. Enova Medical Launches Exos Corporation
7. Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability
8. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
9. ThirdBiotech Networking Group Launches
10. BioReliance Launches Next-Generation Genotoxicity Screening Service
11. Midwest Research Institute Launches Center for Biological Safety and Security (CBS2)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Continuing its award-winning streak, Nerium International, the ... Awards for outstanding creative achievement by its marketing and ... the organization’s top honor, in the Branding category for ... April of this year. The event showcased top speakers ... was awarded a Gold MarCom Award in the Special ...
(Date:11/26/2014)... 25, 2014 Global biostimulants market ... growing at an estimated CAGR of 12.5%. In ... food products with least ecological impacts, farmers are ... to boost crop yield more effectively & efficiently. ... can improve the return on investments. , Leading ...
(Date:11/26/2014)... MA (PRWEB) November 26, 2014 ... collaboration company is proud to announce that Darren Suders ... and Sales. Darren will drive the partner ... positive customer experience. , Darren brings more ... has held key roles in channel operations, from policy ...
(Date:11/26/2014)... Dallas, Texas (PRWEB) November 26, 2014 ... Acid Industry is an in-depth research report on ... analysis, the report introduces Palmitic Acid, basic information, ... overview, policy analysis, and news analysis, etc. ... report analyzes Palmitic Acid market in ...
Breaking Biology Technology:Nerium International™ Wins One Platinum, Two Gold MarCom Awards 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4SoundConnect Appoints Director of Channel Development & Sales 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 3
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:,ONC, NASDAQ: ONCY) ... research group at The Institute of Cancer Research, ... combination treatment schedules,of reovirus and radiation in human ... The paper, entitled "Enhanced In vitro and In ...
... environment and holding it indefinitely in molecular-sized containers has been ... say it represents a novel method of gas storage that ... safely and efficiently. , This is a proof of concept ... just improving on a method that already exists, said U ...
... the economy is not,only heading towards a recession but ... during January. However, biotech held steady,with the Burrill Biotech ... posted a January loss of 9.9%, and the Dow, ... ride out extremely volatile capital,markets with less damage because ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy 2Rounding up gases, nano-style 2January Market Jitters Fails to Derail Biotech 2January Market Jitters Fails to Derail Biotech 3January Market Jitters Fails to Derail Biotech 4
(Date:11/7/2014)... , November 6, 2014 Leading ... for better mobile security revolutionizing online transactions.  Companies in focus ... Holdings Ltd. (NYSE: BABA ), Google Inc. (NASDAQ: ... ), eBay Inc. (NASDAQ: EBAY ) and MasterCard ... NXTD and NXTDW), a biometric authentication company focused on ...
(Date:11/5/2014)... biology in the UTSA College of Sciences, is ... to receive a two-year $300,00 National Science Foundation ... The funding supports President Obama,s BRAIN Initiative, a ... technology that will demystify complex brain processes. ... are broken into the interactions of multiple components, ...
(Date:11/4/2014)... PA) – Temple University School of Medicine announced ... winner, an initiative funded by the Bill & ... Professor of Obstetrics, Gynecology and Reproductive Sciences; and ... Temple University School of Medicine will pursue an ... "Maternal Blood Biomarkers to Assess Fetal Neurodevelopment.", Grand ...
Breaking Biology News(10 mins):Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3Temple University School of Medicine receives Grand Challenges Explorations grant 2
... of burning fossil fuels, running factories and driving cars, ... maple trees growing in the Northeast, according to a ... The sugar maple is the most economically valuable tree ... high-priced lumber, syrup and tourist-attracting fall colors. ...
... burning fossil fuels, running factories and driving cars, has ... trees growing in the Northeast, according to a new ... sugar maple is the most economically valuable tree species ... lumber, syrup and tourist-attracting fall colors. , ...
... or smell, receptors unique to each nerve cell detect the ... process the message to understand what we are smelling or ... it must use many different receptors to sense and interpret ... environments changes in molecular concentrations as small as 0.1 percent, ...
Cached Biology News:Gene therapy prevents the onset of diabetic symptoms in mice 2Gene therapy prevents the onset of diabetic symptoms in mice 3Acid rain causing decline in sugar maples, say researchers 2Acid rain causing decline in sugar maples, say researchers 3Researchers discover how bacteria sense their environments 2
Anti-NeuroD 6 Immunogen: Synthetic peptide. Available Date: 36708...
HOXC11 Antibody...
Anti-MMP-14, catalytic domain, clone LEM-2/15.8 Immunogen: Synthetic peptide: amino acid sequence 218-233 within the catalytic domain Available Date: 38579...
Rabbit anti MMP-13, Hinge Region MMP-13 Hinge Region...
Biology Products: